Elixir Medical Corp

Join us at #CathlabOfTheFuture 2026 Maximizing Outcomes in Heavily Calcified LAD: Breaking Through with Novel Techniques 📍 Portoroz, Slovenia | March 6–7 🗓️ March 6 | 13:30–14:30 Scientific Symposium sponsored by Elixir Medical Moderator: @MohanedEgred Faculty: Irzal Hadzibegovic, @DamianoRegazzo1, Maximilian Will This session will explore innovative strategies for PCI. Speakers will be discussing the importance of vessel function restoration to improve PCI outcomes as well as how to optimize stent expansion regardless of calcium morphology with #LithiX #IVL. #PCI #Bioadaptor #LithiX #IVL #Cardiology The DynamX® Coronary Bioadaptor System is CE mark approved and is not available for sale in the United States. Caution: The DynamX® Sirolimus Eluting Coronary Bioadaptor System is an investigational device in the United States. Limited by Federal (or United States) law to investigational use. The LithiX™ HC-IVL system is CE mark approved and is not available for sale in the United States. PMN 2410 Rev A

Join us at #Euro4C 2026 for a symposium on the role of LithiX Hertz Contact IVL in calcium fragmentation. The session will highlight the mechanism of action for LithiX Hertz Contact IVL, the clinical evidence and real-world case discussions of calcium modification in PCI. Faculty: @HontonB , @JEscaned , @enrico_cerrato , @HawranekMichal , @valeriaparadies 📅 Friday, 27 February 2026 🕓 16:00–17:00 | Main Room, Session ID 41390 #Euro4C2026 #LithiX #IVL #PCI #CalciumModification The LithiX™ HC-IVL system is CE mark approved and is not available for sale in the United States. PMN 2397 Rev A

Join us at DEBS 2026 in Rome, Italy 📅 February 19–20, 2026 Elixir Medical is pleased to participate in this year’s DEBS program with presentations focused on calcium modification and Bioadaptor vs. DCB strategies. 🔹 Live Case: Calcium Modification with LithiX Operator: @BenedittoDi 🔹 Session 15: Innovation Corner: Bioadaptor vs DCB Featuring: G.M. Sangiorgi We look forward to contributing to the discussion on next-generation coronary therapies. PMN 2392 Rev A #DEBS2026 #LithiX #Bioadaptor #IVL #PCI #Cardiology #ElixirMedical

ICYMI: At TCT 2025, Dr. David Erlinge presented new real-world comparative data on PCI outcomes using bioadaptors vs drug-coated balloons (DCB) for de novo coronary lesions. Using propensity score-matched data from the SCAAR registry, this 2-year analysis included a clinically complex population with >70% ACS patients in both treatment arms. “In this study, the bioadaptor was associated with a better 2-year outcome compared to DCB.” – Dr. David Erlinge Primary composite outcome (target segment revascularization, TV-MI, or all-cause mortality): – Bioadaptor: 4.9% – DCB: 9.7% View the full presentation: bit.ly/4kp4HRR The DynamX® Coronary Bioadaptor System is CE mark approved and is not available for sale in the United States. Caution: The DynamX® Sirolimus Eluting Coronary Bioadaptor System is an investigational device in the United States. Limited by Federal (or United States) law to investigational use. PMN 2315 Rev A

Elixir Medical is committed to transforming the care of patients with heart disease, and today we’re rocking red to help raise awareness of the No.1 killer of women – cardiovascular disease. Visit bit.ly/3L75rch to learn more about heart disease and stroke in women and find more ways to support the @American_Heart's initiative. #WearRedDay #americanheartassociation #HeartMonth NPMC 333

How do we overcome the challenge of calcium modification? At GRCI2025, Frédéric Bouisset, Charlotte Trouillet, Pierre Robert, and Benoît Lattuca shared their experiences with LithiX HC-IVL. They discussed the importance of calcium modification in clinical outcomes and detailed the versatility, deliverability, and safety of LithiX as it was used to achieve outstanding results in lesion preparation in two illustrative cases: • A severely calcified lesion with nodular calcium • A long, eccentric, heavy calcified lesion Check out the full recording to see the OCT and IVUS results for yourself! Watch here: youtube.com/watch?v=YoC6YN… #LithiX #Lithotripsy #GRCI2025 #PCI #ElixirMedical The LithiX™ HC-IVL system is CE mark approved and is not available for sale in the United States. CAUTION: Case studies shown are based on individual experiences and results may vary. Results depend on a variety of factors, including patient history, severity of condition, and compliance with instructions. Elixir Medical does not claim that these results demonstrate the safety and effectiveness of the device. PMN 2381 Rev A

Looking forward to this international webinar hosted by InCathLabon February 3, featuring techniques with our novel LithiXHertz Contact IVL. Clinical insights and real-world cases will highlight how this technology fractures calcium and improves vessel compliance. Register and Join us: incathlab.com/en/lives/19-ca… Speakers: @MohanedEgred, @sinning_jan, @JohanBennett2,@charlottetroui2, @MarcoPavani01 & @OjedaOjeda18 #LithiX #IVL #PCI #CalciumModification #Webinar The LithiX™ HC-IVL system is CE Mark approved and not available for sale in the United States.

What a standout case presented by Dr. Marta Bujak (with Dr. Paweł Gąsior) during the “Novel Solutions for CHIP” session at TCT 2025. This complex case focused on a severely calcified and significantly stenosed LAD, where LithiX HC-IVL was used following IVUS-HD and OCT-guided lesion assessment. Imaging revealed thick, concentric calcium with a calcified nodule and >270° arc. Following LithiX delivery and stepwise inflation, both IVUS and OCT confirmed deep and surface-level calcium fractures. A single balloon effectively prepared the lesion, enabling optimal stent expansion and full apposition with no residual stenosis. This case highlights the clinical potential of LithiX in modifying complex calcium, with clear visualization of its effect using dual-modality imaging. See the case presentation: elixirmedical.com/ous/case-studi… #TCT2025 #LithiX #IVL #CalciumModification #Lithotripsy #PCI #ElixirMedical LithiX Hertz Contact Lithotripsy System is CE Mark approved and not for sale in the U.S.

📅 Join us on February 3, 2026| 18:00–19:00 CET for a webinar on the novel Hertz Contact IVL technique for calcium modification in PCI. The session will be moderated by @MohanedEgred (UK) and @sinning_jan (Germany) and will feature international faculty presenting clinical evidence and real-world cases using LithiX HC-IVL. Agenda Highlights: • Introduction: @sinning_jan (Germany) • Technology & Evidence Overview: @JohanBennett2 (Belgium) • Case 1: Long lesion & tortuosity – @charlottetroui2 (France) • Case 2: Multivessel PCI with one device – @MohanedEgred (UK) • Case 3: Uncrossable lesion with Rotablation & LithiX – @MarcoPavani01 (Italy) • Case 4: Nodular calcium modification – @OjedaOjeda18 (Spain) Interactive discussion and Q&A included. 📍 Location: InCathLab 🔗 Register now: incathlab.com/en/lives/19-ca… #Webinar #LithiX #IVL #CalciumModification #PCI #ElixirMedical #Medtech The LithiXTM HC-IVL system is CE Mark approved and not available for sale in the United States.

We're proud to advance our mission of delivering innovative cardiovascular solutions to emerging markets—helping patients in Indonesia receive world-class care without traveling abroad. In late December 2025, a 61-year-old woman who previously sought treatment overseas chose **Bali International Hospital** for her calcified coronary artery disease. She became one of the first in Bali to benefit from **two Elixir Medical breakthroughs**: LithiX™ Hertz Contact IVL— safely fracturing hard calcified plaques with Hertz Contact Stress for optimal vessel prep. -DynamX® Coronary Bioadaptor — restoring natural vessel motion and function, redefining PCI with reduced long-term re-intervention risk. Dr. Tsutomu Fujita (Head of Cardiology, from Sapporo Cardiovascular Clinic): "The Bioadaptor is the future of PCI—better outcomes, fewer re-interventions." Dr. Suma Dewa: "Hertz Contact IVL makes complex calcified cases safer and simpler." In 30–40% of cases with heavy calcification, effective lesion preparation is critical. Elixir technologies are making that possible locally. Thank you to Bali International Hospital for embracing Silicon Valley innovation to transform patient care in Indonesia. #Cardiology #Bioadaptor #DynamX #LithiX #IVL #PCI #CardiovascularInnovation #ElixirMedical #HealthcareAccess Caution: The LithiX™ HC-IVL system and DynamX® Coronary Bioadaptor System are CE Mark approved and not available for sale in the United States. Caution: The DynamX® Sirolimus Eluting Coronary Bioadaptor System is an investigational device in the United States. Limited by Federal (or United States) law to investigational use. PMN 2366 Rev A

Stunning All-Comers IVL Outcomes. Outcomes of the MY-IVL all-comers clinical study showed versatility of LithiX Hertz Contact (HC) Intravascular Lithotripsy (IVL) to safely fragment diverse calcium morphologies in complex patient population resulting in optimal stent expansion. Led by study co-PIs Dr. Tamil Selvan Muthusamy and Dr. Ali Rosli at Cardiac Vascular Sentral Kuala Lumpur Hospital (CVSKL), this clinical study involved: • 64% ACS clinical presentation • 88% severe lesion calcification • 41% eccentric calcific lesions To learn more: bit.ly/3YPoQ9T To review the complete MY-IVL Clinical Study outcomes presentation: bit.ly/4js5K2M LithiX Hertz Contact Lithotripsy System is CE Mark approved and not for sale in the U.S.

Happy New Year — and cheers to 20 years of transforming vascular medicine! This year marks a major milestone for our company, and as we look back, we’re proud of the innovation, research, and clinical progress we’ve achieved together. Here are just a few highlights from an extraordinary year: • Celebrating Our 20th Anniversary • Two decades of pushing boundaries, partnering with clinicians, and unlocking what’s possible in vascular intervention. • DynamX BIOADAPTOR RCT 3-Year & INFINITY-SWEDEHEART R-RCT 2-Year Outcomes • Another strong year of clinical evidence — with long-term RCT data continuing to show improved benefits for patients. • LithiX Hertz Contact Intravascular Lithotripsy (HC-IVL) Launch • Expanding the reach of innovative intravascular lithotripsy technology and advancing treatment options for calcification in complex lesions. • Recognized by Fast Company & Fierce Biotech • A proud moment as we were honored among the year’s most impactful innovators. As we turn the page, we’re filled with gratitude for our partners, clinical collaborators, and team members who bring passion and purpose to this mission every day. Here’s to growth, discovery, collaboration, and progress in 2026. Wishing you a prosperous and hopeful New Year! #HappyNewYear #MedTech #VascularInnovation Caution: The DynamX Sirolimus Eluting Coronary Bioadaptor System is an investigational device in the US and limited by federal (or United States) law to investigational use. LithiX Hertz Contact Lithotripsy System is CE Mark approved and not for sale in the U.S.

Rethink what we leave behind after PCI. At this year’s @GisGulf Annual Conference, physicians will discuss DynamX® bioadaptor — a novel implant that adapts with the vessel, designed to support natural healing and long-term vessel function. Join us for the featured session: Leave the Right Thing Behind: Improving PCI Outcomes with Bioadaptor 🗓 Thursday, November 27 🕑 📍 Cath Lab, GIS Conference Outstanding faculty @Falmutairi2018, @johaniMD, @Sultanotb, Hassan Harbi & @DamianoRegazzo1 discuss how DynamX challenges the limitations of DES, BRS, and DCB by offering a new paradigm in PCI. Join to review the science behind the unique mechanism of action, the clinical evidence, and real-world cases. Then on Friday, hear from Dr. Georgette Zinaty, discussing purposeful leadership and turning disruption into strategic advantage, from 9 to 11 a.m. in Hall B. We look forward to insightful discussions with leaders in interventional cardiology. Don’t miss the opportunity to explore how bioadaptive technology is shaping the future of vascular intervention. #GIS2025 #DynamX #Bioadaptor #PCI #InterventionalCardiology #CathLabInnovation #LeaveTheRightThingBehind #ElixirMedical Caution: The DynamX Sirolimus Eluting Coronary Bioadaptor System is an investigational device in the United States. Limited by Federal (or United States) law to investigational use. DynamX Coronary Bioadaptor System is CE mark approved and not for sale in the US.

FOR POLISH PHYSICIANS: Join us for an upcoming webinar hosted in partnership with Asocjacja Interwencji Sercowo-Naczyniowych (@AISNPL) and Elixir Medical, focused on real-world experiences with LithiX IVL technology. LithiX Hertz Contact Stress IVL - A New Approach to Calcium Modification 🗓️ November 4, 2025 🌐 Register here: aisn.pl/2025-11-04/ Led by @HawranekMichal and @ZenonHuczek, this session will begin with an overview of the LithiX mechanism of action and supporting clinical data. Expert faculty including @HawranekMichal, Grzegorz Sobieszek, Janusz Kochman, @Marta33717088, and Piotr Wańczura will present clinical cases demonstrating how LithiX IVL supports optimal calcium modification in patients with: – Tortuous anatomy – Long lesions – Multi-vessel disease – Nodular and eccentric calcification The session will conclude with a moderated discussion on the clinical application of LithiX in contemporary PCI. #Webinar #LithiX #IVL #CalciumModification #PCI #Cardiology #ElixirMedical #AISN #Poland

Leave nothing behind or leave the right thing in place? Fascinating comparison of drug-coated balloons (DCB) and the bioadaptor in treatment of de novo coronary lesions presented by Dr. @DavidErlinge at @TCTMD 2025. 2-year clinical outcomes of patients undergoing PCI captured in the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) were propensity score-matched for this analysis, with > 70% ACS patients in each arm of the study. “In this study, the bioadaptor was associated with a better 2-year outcome compared to DCB.” Primary composite outcome (target segment revascularization, TV-MI or all-cause mortality): •Bioadaptor: 4.9% •DCB: 9.7% To review the complete presentation: elixirmedical.com/wp-content/upl… Caution: The DynamX Sirolimus Eluting Coronary Bioadaptor System is an investigational device. Limited by Federal (or United States) law to investigational use. DynamX Coronary Bioadaptor System is CE mark approved and not available for sale in the United States. #TCT2025 #DynamX #bioadaptor #PCI #DCB #ElixirMedical

It’s the final day of @TCTMD 2025! We have enjoyed connecting with colleagues from around the world and are looking forward to hearing these podium presentations today. 🗓️ Tuesday, October 28 8:40 AM – Computational Fluid Dynamic and Morphometric Analysis of the Novel DynamX® Bioadaptor System at Baseline and 1-Year Follow-Up (@giuliorus) 📍Presentation Theater 2 | Hall D Session: Cases with the Masters – Acute Coronary Syndromes: Vulnerable Plaque 12:00 PM – DynamX® Bioadaptor Implantation for Treatment of Complex Coronary Artery Disease – Final Results from the DYNAMITE Study (@leoneppmd) 📍Station 5 | Halls B-C Session: Scientific Abstracts – Newer Stent Design Studies 1:00 PM – 2-Year Nationwide Analysis from SWEDEHEART: Comparison of Drug-Coated Balloons and the Bioadaptor in Treatment of De Novo Coronary Lesions @DavidErlinge) 📍Station 7 | Halls B-C Session: Novel Technologies for Transcatheter Coronary Interventions #TCT2025 #Cardiology #Bioadaptor #LithiX #PCI #Innovation #ElixirMedical

Massive update on the shifting PCI paradigm released at @TCTMD 2025. 2-year clinical outcomes of the INFINITY-SWEDEHEART RCT presented by Dr. @DavidErlinge, on behalf of Dr. Stefan James and the INFINITY-SWEDEHEART Investigators. Large (2,400 patients) RCT shows continuing separation of clinical outcomes between patients treated with bioadaptors and those treated with contemporary DES in clinically complex ischemic patients (includes ~77% ACS patients in each arm) now out to 2 years follow up. Sustained treatment benefit following bioadaptor unlocking after 6 months: • Significant reduction in TLF from 6 months to 2 years: Log-rank p = 0.0245 • Significant reduction in TVF from 6 months to 2 years: Log-rank p = 0.0481 • Significant reduction in TLF in ACS from 6 months to 2 years: Log-rank p = 0.0175 To review the full INFINITY-SWEDEHEART RCT 2-year Follow Up clinical results presentation: bit.ly/43FSSPT #TCT2025 #DynamX #bioadaptor #PCI #ElixirMedical

Elixir Medical is live at Day 3 of TCT 2025! Don’t miss these key presentations on Elixir Medical technologies: 🗓️ Monday, October 27 11:00 AM – Challenging Case of Heavily Calcified CTO Treated With New Lithotripsy Device – LithiX Hertz Contact Intravascular Lithotripsy (Daniela Benedetto) 📍Presentation Theater 3 | Hall D Session: Cases with the Masters – CHIP: Novel Solutions for CHIP 11:00 AM – Lessons from Clinical Practice: Novel LithiX Hertz Contact Intravascular Lithotripsy for Calcium Modification of Coronary Lesions (Stefano Galli) 📍Presentation Theater 3 | Hall D Session: Cases with the Masters – CHIP: Novel Solutions for CHIP 11:00 AM – New Kit on the Block: IVUS and OCT Assessment of LithiX Hertz Contact Intravascular Lithotripsy in Complex Calcified Lesion (@Bujak_M) 📍Presentation Theater 3 | Hall D Session: Cases with the Masters – CHIP: Novel Solutions for CHIP 2:00 PM – Patients Treated with the Bioadaptor Compared with a Contemporary Drug Eluting Stent: Long Term Clinical Outcomes of the INFINITY-SWEDEHEART RCT (@DavidErlinge) 📍Main Arena | Hall A Session: Late-Breaking Clinical Science: Session II, in Collaboration with the Journal of the American College of Cardiology 4:50 PM – Hertz Contact Intravascular Lithotripsy for Calcified Coronary Lesions in Real-World Practice: Primary Outcomes of the MY-IVL Study (Tamil Selvan Muthusamy) 📍Innovation Theater | Hall E Session: Innovation Session 13: Innovations in Intravascular Lithotripsy Join us as we advance the conversation on innovation in PCI. See all of Elixir’s presentations: bit.ly/42SoUb7 #TCT2025 #Cardiology #Bioadaptor #LithiX #PCI #Innovation #ElixirMedical

Congratulations Dr. Sahbi Fradi for your insightful presentation of “Calcium Modification in Complex PCI Using the LithiX HC-IVL System” at @TCTMD 2025. This is a great example of resolving a large calcific nodule “with procedural efficiency” and “eliminating the need for capital equipment, particularly well suited for routine use in complex PCI scenarios.” For more information on LithiX Hertz Contact IVL: elixirmedical.com/ous/lithix/ #TCT2025 #LithiX #IVL #Lithotripsy #PCI #ElixirMedical